PTO/SB/21 (07-06)
Approved for use through 09/30/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission

Application Number 10/588,567_ Filing Date August 4, 2006 First Named Inventor Rebecca Fitzgerald Art Unit Not Yet Assigned **Examiner Name** Not Yet Assigned Attorney Docket Number 30699/42218

	ENCLOSURES (Check all that apply)				
Fee Transmittal Form		Drawing(s)		After Allowance Communication to TC	
Fee Attached		Licensing-related Papers		Appeal Communication to Board of Appeals and Interferences	
Amendme	nt/Reply	Petition		Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)	
Afte	r Final	Petition to Convert to a Provisional Application		Proprietary Information	
Affid	lavits/declaration(s)	Power of Attorney, Revocat Change of Correspondence	ion Address	Status Letter	
Extension	of Time Request	Terminal Disclaimer		X Other Enclosure(s) (please Identify below):	
Express A	bandonment Request	Request for Refund		Copy of International Preliminary Report on Patentability and Written	
x Information	n Disclosure Statement	CD, Number of CD(s)		Opinion of the International Searching Authority	
Certified C Document	copy of Priority (s)	Landscape Table on CD Form PTO/SB/08 postcard			
	lissing Parts/ e Application	Remarks			
Reply to Missing Parts under 37 CFR 1.52 or 1.53					
				,	
SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT					
Firm Name MARSHALL, GERS		TEIN & BORUN LLP			
Signature Relatel.					
Printed name	Nabeela R. McMillia	า			
Date	October 4, 2006		Reg. No.	43,363	

I hereby certify that this paper (along with an the date shown below with sufficient postage Box 1450, Alexandria, VA 22313-1450.	by paper referred to as being attached or enclosed) is being deposited with the U.S. Postal Service on a sa First Class Mail, in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O.
Dated: October 4, 2006	Signature:(Nabeela R. McMillian)

I he oy certify that this paper (along with any paper referred to as being attached of ciclosed) is being deposited with the U.S. Postal Service on the date shown serious with sufficient postage as First Class Mail, in an envelope addressed to:

MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Dated: October 4, 2006 Signature:

Docket No.: 30699/42218

(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of: Rebecca Fitzgerald et al.

Application No.: 10/588,567

2006 Art Unit: 0

Filed: August 4, 2006

Medicaments for Treating Barrett's

Oesophagus

Examiner: Not Yet Assigned

Confirmation No.: Not

INFORMATION DISCLOSURE STATEMENT (IDS)

MS Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

For:

In accordance with 37 CFR 1.97, Applicant(s) hereby make of record the following additional documents. A PTO Form SB/08 and a full copy of each of the documents required under 37 CFR 1.98(a)(2) accompany this statement.

Applicant(s) have become aware of the following documents, cited in a Written Opinion of the International Searching Authority issued <u>August 22, 2006</u>, during the prosecution of International Application No. PCT/GB2005/000594, which corresponds to the above referenced application, and in accordance with 37 CFR 1.97(c) and (e)(1) or (b)(3), hereby submit(s) these documents for the Examiner's consideration. These documents are cited on the enclosed PTO Form SB/08, and a copy of the Written Opinion and of each document required under 37 CFR 1.98(a)(2) cited thereon are enclosed as well.

This statement is not to be interpreted as a representation that the cited documents are material, that an exhaustive search has been conducted, or that no other relevant information exists. Nor shall the citation of any document herein be construed *per se*

Application No.: 10/588,567 Docket No.: 30699/42218

as a representation that such document is prior art. Moreover, Applicant(s) understand(s) the Examiner will make an independent evaluation of the cited documents.

This Information Disclosure Statement is filed within three months of the date of entry of the national stage of an international application as set forth in 37 CFR 1.491 (37 CFR 1.97(b)(2)).

The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 13-2855, under Order No. 30699/42218. A duplicate copy of this paper is enclosed.

Dated: October 4, 2006

Respectfully submitted,

Nabeela R. McMillian

Registration No.: 43,363

MARSHALL, GERSTEIN & BORUN LLP

233 S. Wacker Drive, Suite 6300

Sears Tower

Chicago, Illinois 60606-6357

(312) 474-6300

Attorney for Applicant

PTO/SB/08a/b (07-06) Approved for use through 09/30/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known Substitute for form 1449A/B/PTO 10/588,567 Application Number INFORMATION DISCLOSURE Filing Date August 4, 2006 STATEMENT BY APPLICANT First Named Inventor Rebecca Fitzgerald Art Unit Not Yes Assigned (Use as many sheets as necessary) Examiner Name Not Yet Assigned Sheet 1 of 2 Attorney Docket Number 30699/42218

	U.S. PATENT DOCUMENTS				
Examiner Initials*	Cite No.1	Document Number Number-Kind Code ² (<i>if known</i>)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	ļ				

	FOREIGN PATENT DOCUMENTS .					
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
		WO-98/08546		Chambon et al.		\vdash
		WO-91/11172	08-08-1991	Stella et al.		
		WO-02/098398		Barth et al.		
		WO-98/55148	12-10-1998	Vadecruys et al.		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language Translation is attached.

		NON PATENT LITERATURE DOCUMENTS			
Initials No.1 magazine, journal, serial, symposium, catalog, etc.),		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²		
		Kubota et al., Exp. Cell Res., 263:163-172 (2001)			
		Muller et al., Cancer Lett., 113(1-2):95-101 (1997) (ABSTRACT ONLY)			
		Niederreither et al., Nat. Genet., 31:84-88 (2002) (ABSTRACT ONLY)			
		Sampliner et al., "A Phase II Trial of 13-CIS Retinoic Acid (Isotretinoin) in Barrett's			
		Esophagus", Gastroenterology, 94(4):A396 (1988) (ABSTRACT ONLY)			
		Garewal et al., "Effect of Potential Differentiating Agents on the Growth of Barrett's			
Esophagus-Derived Epithelial Cell Cultures", Clinical Research, 36(1):131A (1986)		Esophagus-Derived Epithelial Cell Cultures", Clinical Research, 36(1):131A (1988)			
		Lord et al., Surgery, 129:267-276 (2001)			
	Garewal et al., J. Natl. Cancer Inst. Monogr., 13:51-54 (1992)				
		Tsai et al., "Retinoic Acid Receptor Expression in Barrett's Esophagus and Barrett's Associated Adenocarcinomas", Proc. Am. Assoc. Cancer Res. Annual Meeting, 40:309 (1999) (ABSTRACT ONLY)			
Adenocarcinoma", Preventive Medicine, 17(2):244 (1988) (ABSTRACT ONLY) Jetten et al., Laboratory Investigation, 56(6):654-664 (1987) Shindoh et al., Obstet. Gynecol., 85:721-728 (1995) Darwiche et al., Endocrinology, 134:2018-2025 (1994)		Garewal et al., "Studies on Barrett's Esophagus a Unique Metaplastic Premalignant Lesion for Adenocarcinoma", Preventive Medicine, 17(2):244 (1988) (ABSTRACT ONLY)			
		Jetten et al., Laboratory Investigation, 56(6):654-664 (1987)			
		Shindoh et al., Obstet. Gynecol., 85:721-728 (1995)			
		Darwiche et al., Endocrinology, 134:2018-2025 (1994)			
		Rearick et al., Environmental Health Perspectives, 80:229-237 (1989)			
		Castonguay et al., Environ. Health Perspect., 103:254-258 (1995)			
		Biesalski et al., Eur. J. Med. Res., 6:391-398 (2001)			
		Wan et al., Anticancer Research, 21;2657-2664 (2001)			
		Khuri et al., Cancer Epidemiol. Biomarkers Prev., 10:311-318 (2001)			
		Varani et al., Skin Pharmacol., 4:254-261 (1991)			
		Kikonyogo et al., Eur. J. Biochem., 262:704-712 (1999)			
Examiner		Date			

Signature

Considered

PTO/SB/08a/b (07-06)
Approved for use through 09/30/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
der the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. That the substitute for form 1449A/B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 2

Complete if Known		
Application Number	10/588,567	
Filing Date August 4, 2006		
First Named Inventor	Rebecca Fitzgerald	
Art Unit	Not Yes Assigned	
Examiner Name	Not Yet Assigned	
Attorney Docket Number	30699/42218	

White et al., Proc. Natl. Acad. Sci. USA, 97(12):6403-6408 (2000)	
 Wang et al., Arch. Biochem. Biophys., 401:235-243 (2002)	
 Klaassen et al., Clin. Cancer Res., 7:1017-1025 (2001)	
Taimi et al., J. Biol. Chem., 279(1):77-85 (2004)	
 Mira-Y-Lopez et al., J. Cell. Physiol., 185:302-309 (2000)	
Lampen et al., J. Pharm. Exp. Ther., 295(3):979-985 (2000)	
 Schapira et al., Proc. Natl. Acad. Sci. USA, 97(3):1008-1013 (2000)	
2010 2011, 07 (0):1000-1013 (2000)	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Application No. (if known): 10/588,567

Attorney Docket No.: 30699/42218

Certificate of Mailing under 37 CFR 1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to:

> MS Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

on	October 4, 2006
	Data

1 Cala flu	li.
Signa	ture
Nabeela R.	
Typed or printed name of p	person signing Certificate
43,363	(312) 474-6638
Registration Number, if applicable	Telephone Number

Note: Each paper must have its own certificate of mailing, or this certificate must identify each submitted paper.

IDS (Citation) by Applicant (30 References) (2 pages); postcard